Vivos Therapeutics, Inc. (VVOS) Reports Q3 Loss, Beats Revenue Estimates
Vivos Therapeutics reported a Q3 loss of $0.07 per share, beating consensus estimates of $0.30 loss by 76.67%. Revenue came in at $6.41 million, surpassing estimates by 17.15%, though down from $6.78 million year-ago. The stock has declined 95.2% year-to-date and carries a Zacks Rank #3 (Hold) rating with mixed estimate revisions.